Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Moderna vaccine induces robust immune response against SARS-CoV-2

The race to develop an effective vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is on, and one of the potential candidates shows promise in inducing an immune response.

15 Jul 2020

Obesity and metabolic syndrome increase risk for severe influenza, COVID-19

Metabolic syndrome increases the risk of severe disease from viral infection, according to a review of the literature performed by a team of researchers from St. Jude Graduate School of Biomedical Sciences and the University of Tennessee Health Science Center, both in Memphis.

15 Jul 2020

New mass spectrometry-based test detects coronavirus in gargle solutions of patients

Pharmacists at Martin Luther University Halle-Wittenberg have succeeded in detecting small amounts of coronavirus SARS-CoV-2 using mass spectrometry.

15 Jul 2020

New technology allows quick and cost-effective identification of cancer biomarkers

A new way of identifying cancer biomarkers has been developed by researchers at Lund University in Sweden. The new technology allows very sensitive, quick and cost-effective identification of cancer biomarkers.

15 Jul 2020

Common FDA-approved drug may be a powerful tool in fighting COVID-19

A common drug, already approved by the Food and Drug Administration, may also be a powerful tool in fighting COVID-19, according to research published this week in Antiviral Research.

15 Jul 2020

Nanotechnology plays major role in COVID-19 vaccine development

From mRNA vaccines entering clinical trials, to peptide-based vaccines and using molecular farming to scale vaccine production, the COVID-19 pandemic is pushing new and emerging nanotechnologies into the frontlines and the headlines.

15 Jul 2020

10x Genomics launches Chromium Single Cell Immune Profiling v2 product to fight COVID-19

10x Genomics strengthened the research toolkit of scientists around the globe today with the launch of its Chromium Single Cell Immune Profiling v2 product.

15 Jul 2020

Antibodies to SARS-CoV-2 disappear within three months

The question is, does this infection confer lasting immunity? A new study published in the journal Clinical Microbiology and Infection in July 2020 appears to show that it does not, with antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disappearing within three months of infection.

15 Jul 2020

Experimental vaccine induces neutralizing antibodies against SARS-CoV-2

An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published online today in The New England Journal of Medicine.

15 Jul 2020

Certain antibodies may cause the dangerous part of COVID-19 disease

A new study out of the Netherlands and published on the preprint server bioRxiv* in July 2020 discusses the commonly observed phenomenon of COVID-19 progression at 1-2 weeks from the onset of the earliest symptoms. This is ascribed to the overactivation of the inflammatory signaling cascade triggered by a hyperactive adaptive immune reaction, commonly called the cytokine storm.

15 Jul 2020

Llama nanobodies block SARS-CoV-2 infection in vitro

Now, a team of scientists at the United Kingdom's Rosalind Franklin Institute may have a surprising solution for the coronavirus pandemic, which has killed more than 574,000 people worldwide.

14 Jul 2020

Cold sensitivity of SARS-CoV-2 could impact vaccine studies

Researchers at Duke University in Durham, USA, have made an important discovery about the spike protein on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could have a broad impact on vaccine studies.

14 Jul 2020

Absolute Antibody and University of Zurich partner to offer novel SARS-CoV-2 sybodies

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain (RBD) of SARS-CoV-2, the coronavirus that causes COVID-19.

From Absolute Antibody Ltd 14 Jul 2020

A new measles-based COVID-19 vaccine

Now, a new study by researchers from Germany's Paul Ehrlich Institute and published on the preprint server bioRxiv in July 2020 describes a potential vaccine based on the measles vaccine, which elicits both an antibody response and cellular immunity against the virus. This also protects against the measles virus. This could be a significant weapon in the fight against these two threats.

14 Jul 2020

Current assays reflect non-neutralizing antibodies, finds study

Several serologic tests have been developed to help diagnose the presence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), either currently or in the past. However, all of them are not equally effective.

14 Jul 2020

Researchers stabilize the closed SARS-CoV-2 spike trimer

Now, a new study by researchers at Janssen Vaccines & Prevention BV and Leiden University and published on the preprint server bioRxiv uses cryoEM to reveal the structure of this trimer, in order to support both vaccine development and diagnostic testing based on antibody production.

14 Jul 2020

Coronavirus disease immunity fades within a few months, study finds

The coronavirus disease (COVID-19) has spread rapidly across the globe, with more than 13 million people infected. Of these, an estimated 7 million have recovered from the viral infection. However, it was unclear whether being exposed to the virus would provide long-lasting immunity. Now, a new study says that SARS-CoV-2 immunity may only last for months.

13 Jul 2020

Altimmune announces positive preclinical results of intranasal COVID-19 vaccine candidate

Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced positive results from the preclinical studies conducted in mice at the University of Alabama at Birmingham of its intranasal COVID-19 vaccine candidate, AdCOVID.

13 Jul 2020

Scientists discover common molecular feature found in SARS-CoV-2 neutralizing antibodies

A team led by scientists at Scripps Research has discovered a common molecular feature found in many of the human antibodies that neutralize SARS-CoV-2, the coronavirus that causes COVID-19.

13 Jul 2020

Serology distinguishes children with MIS-C associated with COVID-19

Researchers in the United States say that measuring antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may help to distinguish between multisystem inflammatory syndrome in children (MIS-C) and other clinically similar syndromes.

13 Jul 2020